March 15, 2017
OptiBiotix confimrs new board members
OptiBiotix has confirmed today that Per Rehné and Christina Wood have been appointed to the Board of OptiBiotix. The company in January announced naming the new members.
Pharmaceuticals, Biotechnology and Life Sciences
Category: Approval
March 14, 2017
Market analyst puts focus on four major players in the Drug Manufacturers space
Ahead of Tuesday’s trading session, Stock-Callers.com puts focus on four major players in the Drug Manufacturers space.
March 14, 2017
Private companies AMO Pharma, Renedis Pharmaceutical team up to develop RND-001 for rare genetic diseases
AMO Pharma Limited and Ranedis Pharmaceuticals,two privately held U.S. pharma companies have partnered up to develop RND-001 for rare genetic diseases, including certain lysosomal storage disorders and other diseases affecting the central nervous system.
March 14, 2017
Innovative treatments and therapies from cannabis industry
The expansion of product lines and enhanced product development are fueling rising revenues and overall growth in the swelling cannabis market despite recent ambiguous reports of direction of the federal impact on the legal marijuana market
March 14, 2017
FDA OK’s Novartis’s breast cancer drug
The US Food and Drug Administration (FDA) has approved Novartis’s Kisqali (ribociclib, formerly known as LEE011) in combination with an aromatase inhibitor as initial endocrine-based therapy for treatment of postmenopausal women with hormone receptor positive, human epidermal growth factor receptor-2 negative (HR+/HER2-) advanced or metastatic breast cancer.
March 13, 2017
Mylan, Genentech, Hoffmann-La Roche settle over Herceptin
Mylan has agreed to the terms of a global settlement with Genentech, Inc. and F. Hoffmann-La Roche Ltd. related to patents for Herceptin (trastuzumab), which provides Mylan with global licenses for its trastuzumab product.
March 13, 2017
Biotechnology companies stocks report
iShares NASDAQ Biotechnology exchange-traded fund has gained 13% so far this year, more than double the SPDR S&P 500 ETF’s 6.3% rise, as the potential for new drugs and mergers and acquisitions has rekindled interest in the beaten-down sector.
March 13, 2017
Data on heart benefits of Amgen drug is key to unlocking sales
Data that should help unlock the sales potential of a potent new cholesterol medicine will be unveiled at the American College of Cardiology meeting this week as the future of the only rival drug rests with the courts in an ongoing patent dispute.
March 13, 2017
Ipsen wins MHRA’s approval for its breast cancer drug
Medicines and Healthcare Products Regulatory Agency (MHRA) in the UK, in coordination with fourteen other European regulatory agencies, has approved a new indication for Ipsen’s Decapeptyl as adjuvant treatment in combination with tamoxifen or an aromatase inhibitor, of endocrine-responsive early-stage breast cancer in women at high-risk of recurrence who are confirmed as pre-menopausal after completion of chemotherapy.
March 13, 2017
TiGenix’s hearth attack study confirms the long term safety
TiGenix has found in its acute hearth attack study that allogenic cardiac stem cells can be transplanted safely through the coronary tree.